NextCell Pharma AB (FRA:65G)
Germany
· Delayed Price · Currency is EUR 0.0523
-0.0040 (-7.10%)
At close: Dec 5, 2025
NextCell Pharma AB Company Description
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden.
Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes.
The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.
NextCell Pharma AB
| Country | Sweden |
| Founded | 2014 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 24 |
| CEO | Mathias Svahn |
Contact Details
Address: Karolinska Institutet Science Park Huddinge, Stockholm County 141 57 Sweden | |
| Phone | 46 87 35 55 95 |
| Website | nextcellpharma.com |
Stock Details
| Ticker Symbol | 65G |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | September - August |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mathias Svahn | Chief Executive Officer |
| Patrik Fagerholm | Chief Financial Officer |